Emcure Says It Will Continue Growth Momentum In FY22 By Deepening Product Portfolio, Digital Focus

Author : Ajay Sinha | Published On : 25 Nov 2021

Emcure Pharmaceuticals, one of the fastest-growing drug makers by sales in the domestic market, is planning to strengthen its product portfolio with new launches, line extensions of existing brands and focus on digital sales.

The privately held Pune-based company aims to bring first to market specialty or differentiated generic drugs through the company’s own R&D efforts and innovative molecules through in-licensing partnerships.

In an interview to Moneycontrol, Namita Thapar, Executive Director, Emcure, who manages the India business, said that the company was able to grow above the market in FY21, despite COVID-related disruptions. During normal times, the Indian market grows around 10 percent.

Read more at https://www.moneycontrol.com/news/business/companies/emcure-says-it-will-continue-growth-momentum-in-fy21-by-deepening-product-portfolio-digital-focus-7055101.html